|
WO2020187341A1
|
|
Use of epidermal growth factor in diabetic foot ulcer treatment
|
|
CA3110173A1
|
|
Use of ghrp-6 as late cardioprotective and cardiac restoration medicament
|
|
BR112020022784A2
|
|
hepatitis b vaccine transnasal administration system
|
|
WO2019129314A1
|
|
Interleukin-15 activity antagonist peptide
|
|
WO2018177446A2
|
|
Soy plants comprising the transgenic event cigbdt-def1 or cigbis-def5
|
|
US2020297840A1
|
|
Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
|
|
WO2017050302A1
|
|
Stereotactic frame for limbs
|
|
CU20150077A7
|
|
COMPOSITION FOR THE TREATMENT OF PLANT DISEASES
|
|
NZ722092A
|
|
Conjugate comprising erythropoietin and a branched polymer structure
|
|
US2016157750A1
|
|
Feet positioning system for magnetic resonance imaging studies
|
|
SI2915541T1
|
|
Vesicles which include epidermal growth factor and compositions that contain same
|
|
MX2014003892A
|
|
Amino acid sequences for controlling pathogens.
|
|
MX2014002214A
|
|
Use of the pacap as a molecular adjuvant for vaccines.
|
|
MX2013015206A
|
|
Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases.
|
|
CA2818027A1
|
|
Vaccine composition for controlling ectoparasite infestations
|
|
AU2011235369A1
|
|
Method for inhibiting HIV replication in mammal and human cells
|
|
BRPI0908489A2
|
|
use of chemical compounds and method for designing chemical compounds that attenuate or inhibit dengue virus infection
|
|
AU2006331226A1
|
|
Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations
|
|
AU2006331224A1
|
|
Pharmaceutical compositions containing protein NMA0939
|
|
AU2005287757A1
|
|
Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
|
